← Leaderboards
James A Tumlin
Emory University
$1,387,334
Attributed
$1,387,334
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $300K · FY2005–23$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,387,334 · 4
By mechanism
R01$1,029,440 · 1
R43$299,999 · 1
M01$57,895 · 2
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Michael J Kuhar$11,767,746
- Andrew S. Neish$13,307,399
- Charles D Searles$3,780,630
- Douglas C Wallace$28,541,550
- David C Pallas$4,571,913
Others in their field
Top investigators on “Human Therapy Evaluation”
- Lawrence Corey · Fred Hutchinson Cancer Center$368,153,539
- David Heimbrook · Leidos Biomedical Research, Inc.$241,598,366
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barbara Driver · Westat, Inc.$206,347,735
- Carol Nesel · Westat$188,148,170
- Constance Ann Benson · University Of California, San Diego$179,950,251
Research focus
Human Therapy EvaluationHuman SubjectHemodialysisClinical ResearchOmega 3 Fatty AcidPostoperative ComplicationsThrombosisCardiovascular Disorder PreventionFlow CytometryFluorocarbon PolymersMedical Implant ScienceNutrition Related TagPlatelet ActivationBiomarkerDietary LipidDisease /Disorder Proneness /RiskBlood LipoproteinDiet TherapyClinical TrialsArteriovenous Shunt SurgeryDosageImplantInflammationUnsaturated Fatty Acids
Grant awards (7)
Enhanced renal dialysis membrane performance using lipocalin modified substrates$299,999
R43 · FY2023 · DK · contact PI
RAPAMYCIN IN THE TREATMENT OF GLOMERULOPATHY$248
M01 · FY2006 · RR · contact PI
RAPAMYCIN IN THE TREATMENT OF GLOMERULOPATHY$10,525
M01 · FY2005 · RR
Rapamycin in the Treatment of Glomerulopathy$47,122
M01 · FY2004 · RR
PREVENTION OF GRAFT FAILURE TO DIETARY N-3 FATTY ACIDS$348,781
R01 · FY2002 · HL
PREVENTION OF GRAFT FAILURE TO DIETARY N-3 FATTY ACIDS$343,092
R01 · FY2001 · HL
PREVENTION OF GRAFT FAILURE TO DIETARY N-3 FATTY ACIDS$337,567
R01 · FY2000 · HL